FindTrial
Sign In

Electric Field Therapy

PROCEDURE2 trials

Sponsors

University of California, Davis, Northwestern University

Conditions

Adult Brain GlioblastomaAnaplastic (Malignant) MeningiomaAtypical MeningiomaGrade II MeningiomaGrade III MeningiomaRecurrent Adult Brain NeoplasmRecurrent MeningiomaSupratentorial Meningioma

Phase 2

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse
WithdrawnNCT02348255
University of California, DavisAdult Brain Glioblastoma, Recurrent Adult Brain Neoplasm
Start: 2016-01-31End: 2017-01-31Updated: 2018-01-09
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
RecruitingNCT02847559
Northwestern UniversityAnaplastic (Malignant) Meningioma, Atypical Meningioma, Grade III Meningioma +3
Start: 2016-08-01End: 2026-12-31Target: 27Updated: 2025-06-27

Related Papers

NCOG-52. TUMOR TREATING FIELDS IN MENINGIOMA
Neuro-Oncology2020-11-011 citations
CTNI-59. FIRST SAFETY ANALYSIS OF ANAPLASTIC MENINGIOMA PATIENTS TREATED WITH TUMOR TREATING FIELDS (TTFIELDS)
Neuro-Oncology2020-11-01
ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY
Neuro-Oncology2018-11-011 citations
Abstract CT081: Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase II study
Cancer Research2018-07-01
ACTR-19. A PHASE 2 STUDY OF TUMOR TREATING FIELDS AND BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA
Neuro-Oncology2017-11-01